700 Quince Orchard Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,543
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. John Joseph Trizzino B.S., M.B.A. | President & COO | 641.22k | N/A | 1960 |
Mr. James Patrick Kelly C.F.A. | Executive VP, CFO & Treasurer | 644.32k | N/A | 1966 |
Mr. Stanley Charles Erck | Advisor | 1.09M | N/A | 1948 |
Mr. John Charles Jacobs M.B.A. | CEO & Director | N/A | N/A | 1967 |
Mr. Richard P. Crowley | Executive VP & COO | N/A | N/A | 1957 |
Mr. Troy Morgan Esq., J.D. | Senior VP & Chief Compliance Officer | N/A | N/A | 1971 |
Mr. Mark Casey | Executive VP, Chief Legal Officer & Corporate Secretary | N/A | N/A | N/A |
Ms. Erika S. Trahan | Associate Director of Investor & Public Relations | N/A | N/A | N/A |
Mr. Ian J. Watkins | Executive VP & Chief Human Resources Officer | N/A | N/A | 1963 |
Ms. Silvia Taylor M.B.A. | Executive VP and Chief Corporate Affairs & Advocacy Officer | N/A | N/A | N/A |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax, Inc.’s ISS governance QualityScore as of 1 April 2024 is 4. The pillar scores are Audit: 6; Board: 4; Shareholder rights: 5; Compensation: 5.